Increased percentages of PD-1 on CD4+ T cells is associated with higher INF-γ production and altered IL-17 production in patients with systemic lupus erythematosus

Scandinavian Journal of Rheumatology

Volumn 43, Issue 4, 2014, Pages 307-313

  Dolff, S ^a   Quandt, D ^a   Feldkamp, T ^a   Jun, C ^a   Mitchell, A ^a   Hua, F ^a   Specker, C ^b   Kribben, A ^a   Witzke, O ^a   Wilde, B ^a  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

^b Eye Hospital   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 17; PROGRAMMED DEATH 1 RECEPTOR; PDCD1 PROTEIN, HUMAN;

ADULT; ARTICLE; CD4+ T LYMPHOCYTE; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE ACTIVITY; FEMALE; FLOW CYTOMETRY; GENE; GENE EXPRESSION; HUMAN; IN VITRO STUDY; LUPUS ERYTHEMATOSUS NEPHRITIS; MALE; PRIORITY JOURNAL; PROGRAMMED DEATH 1 GENE; SYSTEMIC LUPUS ERYTHEMATOSUS; METABOLISM; MIDDLE AGED;

ADULT; CD4-POSITIVE T-LYMPHOCYTES; FEMALE; FLOW CYTOMETRY; HUMANS; INTERFERON-GAMMA; INTERLEUKIN-17; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MIDDLE AGED; PROGRAMMED CELL DEATH 1 RECEPTOR;

EID: 84905463071     PISSN: 03009742     EISSN: 15027732     Source Type: Journal    
DOI: 10.3109/03009742.2013.869830     Document Type: Article

References (33)

1. Abbas AK, Murphy KM, Sher A. Functional diversity of helper T lymphocytes. Nature 1996;383:787-93.
2. Viallard JF, Pellegrin JL, Ranchin V, Schaeverbeke T, Dehais J, Longy-Boursier M, et al. Th1 (IL-2, interferon-gamma (IFNgamma)) and Th2 (IL-10, IL-4) cytokine production by peripheral blood mononuclear cells (PBMC) from patients with systemic lupus erythematosus (SLE). Clin Exp Immunol 1999;115:189-95.
3. Wan B, Nie H, Liu A, Feng G, He D, Xu R, et al. Aberrant regulation of synovial T cell activation by soluble costimulatory molecules in rheumatoid arthritis. J Immunol 2006;177:8844-50.
4. Saresella M, Marventano I, Longhi R, Lissoni F, Trabattoni D, Mendozzi L, et al. CD4CD25FoxP3PD1- regulatory T cells in acute and stable relapsing-remitting multiple sclerosis and their modulation by therapy. FASEB J 2008;22:3500-8.
5. Greenwald RJ, Freeman GJ, Sharpe AH. The B7 family revisited. Annu Rev Immunol 2005;23:515-48.
6. Agata Y, Kawasaki A, Nishimura H, Ishida Y, Tsubata T, Yagita H, et al. Expression of the PD-1 antigen on the surface of stimulated mouse T and B lymphocytes. Int Immunol 1996;8:765-72.
7. Freeman GJ, Long AJ, Iwai Y, Bourque K, Chernova T, Nishimura H, et al. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med 2000;192:1027-34.
8. Latchman Y, Wood CR, Chernova T, Chaudhary D, Borde M, Chernova I, et al. PD-L2 is a second ligand for PD-1 and inhibits T cell activation. Nature Immunol 2001;2:261-8.
9. Nishimura H, Minato N, Nakano T, Honjo T. Immunological studies on PD-1 deficient mice: implication of PD-1 as a negative regulator for B cell responses. Int Immunol 1998;10:1563-72.
10. Keir ME, Francisco LM, Sharpe AH. PD-1 and its ligands in T-cell immunity. Curr Opin Immunol 2007;19:309-14.
11. Hatachi S, Iwai Y, Kawano S, Morinobu S, Kobayashi M, Koshiba M, et al. CD4 PD-1 T cells accumulate as unique anergic cells in rheumatoid arthritis synovial fluid. J Rheumatol 2003;30:1410-19.
12. Kobayashi M, Kawano S, Hatachi S, Kurimoto C, Okazaki T, Iwai Y, et al. Enhanced expression of programmed death-1 (PD-1)/ PD-L1 in salivary glands of patients with Sjogren's syndrome. J Rheumatol 2005;32:2156-63.
13. Oikawa T, Takahashi H, Ishikawa T, Hokari A, Otsuki N, Azuma M, et al. Intrahepatic expression of the co-stimulatory molecules programmed death-1, and its ligands in autoimmune liver disease. Pathol Int 2007;57:485-92.
14. Kasagi S, Kawano S, Okazaki T, Honjo T, Morinobu A, Hatachi S, et al. Anti-programmed cell death 1 antibody reduces CD4PD-1 T cells and relieves the lupus-like nephritis of NZB/W F1 mice. J Immunol 2010;184:2337-47.
15. Bertsias GK, NakouM, Choulaki C, Raptopoulou A, Papadimitraki E, Goulielmos G, et al.Genetic, immunologic, and immunohistochemical analysis of the programmed death 1/programmed death ligand 1 pathway in human systemic lupus erythematosus. Arthritis Rheum 2009;60:207-18.
16. Kristjansdottir H, Steinsson K, Gunnarsson I, Grondal G, Erlendsson K, Alarcn-Riquelme ME. Lower expression levels of the programmed death 1 receptor on CD4CD25 T cells and correlation with the PD-1.3A genotype in patients with systemic lupus erythematosus. Arthritis Rheum 2010;62:1702-11.
17. Prokunina L, Castillejo-Lpez C, Oberg F, Gunnarsson I, Berg L, Magnusson V, et al. A regulatory polymorphism in PDCD1 is associated with susceptibility to systemic lupus erythematosus in humans. Nature Genet 2002;32:666-9.
18. Liu M-F, Weng C-T, Weng M-Y. Variable increased expression of program death-1 and program death-1 ligands on peripheral mononuclear cells is not impaired in patients with systemic lupus erythematosus. J Biomed Biotechnol 2009;2009:406136.
19. Wang J, Yoshida T, Nakaki F, Hiai H, Okazaki T, Honjo T. Establishment of NOD-Pdcd1-/- mice as an efficient animal model of type I diabetes. Proc Natl Acad Sci USA 2005;102:11823-8.
20. Latchman YE, Liang SC, Wu Y, Chernova T, Sobel RA, KlemmM, et al. PD-L1-deficient mice show that PD-L1 on T cells, antigenpresenting cells, and host tissues negatively regulates T cells. Proc Natl Acad Sci USA 2004;101:10691-6.
21. Nakae S, Suto H, Iikura M, Kakurai M, Sedgwick JD, Tsai M, et al. Mast cells enhance T cell activation: importance of mast cell costimulatory molecules and secreted TNF. J Immunol 2006; 176:2238-48.
22. Annunziato F, Cosmi L, Santarlasci V, Maggi L, Liotta F, Mazzinghi B, et al. Phenotypic and functional features of human Th17 cells. J Exp Med 2007;204:1849-61.
23. Witowski J, Pawlaczyk K, Breborowicz A, Scheuren A, Kuzlan-Pawlaczyk M, Wisniewska J, et al. IL-17 stimulates intraperitoneal neutrophil infiltration through the release of GRO alpha chemokine from mesothelial cells. J Immunol 2000;165:5814-21.
24. Woltman AM, de Haij S, Boonstra JG, Gobin SJ, Daha MR, van Kooten C. Interleukin-17 and CD40-ligand synergistically enhance cytokine and chemokine production by renal epithelial cells. J Am Soc Nephrol 2000;11:2044-55.
25. Gaffen SL. An overview of IL-17 function and signaling. Cytokine 2008;43:402-7.
26. Abdulahad WH, Stegeman CA, Limburg PC, Kallenberg CGM. Skewed distribution of Th17 lymphocytes in patients with Wegener's granulomatosis in remission. Arthritis Rheum 2008; 58:2196-205.
27. Fitch E, Harper E, Skorcheva I, Kurtz SE, Blauvelt A. Pathophysiology of psoriasis: recent advances on IL-23 and Th17 cytokines. Curr Rheumatol Rep 2007;9:461-7.
28. Kebir H, Kreymborg K, Ifergan I, Dodelet-Devillers A, Cayrol R, Bernard M, et al. Human TH17 lymphocytes promote blood-brain barrier disruption and central nervous system inflammation. Nature Med 2007;13:1173-5.
29. Schmechel S, Konrad A, Diegelmann J, Glas J, Wetzke M, Paschos E, et al. Linking genetic susceptibility to Crohn's disease with Th17 cell function: IL-22 serum levels are increased in Crohn's disease and correlate with disease activity and IL23R genotype status. Inflamm Bowel Dis 2008;14:204-12.
30. Shen H, Goodall JC, Hill Gaston JS. Frequency and phenotype of peripheral blood Th17 cells in ankylosing spondylitis and rheumatoid arthritis. Arthritis Rheum 2009; 60:1647-56.
31. Yang J, Chu Y, Yang X, Gao D, Zhu L, Yang X, et al. Th17 and natural Treg cell population dynamics in systemic lupus erythematosus. Arthritis Rheum 2009;60:1472-83.
32. Trabattoni D, Saresella M, Pacei M, Marventano I, Mendozzi L, Rovaris M, et al. Costimulatory pathways in multiple sclerosis: distinctive expression of PD-1 and PD-L1 in patients with different patterns of disease. J Immunol 2009;183: 4984-93.
33. Said EA, Dupuy FP, Trautmann L, Zhang Y, Shi Y, El-Far M, et al. Programmed death-1-induced interleukin-10 production by monocytes impairs CD4+ T cell activation during HIV infection. Nature Med 2010;16:452-9.